By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ocata Therapeutics (Formerly Known As Advanced Cell Technology) 

33 Locke Drive

Marlborough  Massachusetts   01752  U.S.A.
Phone: 580-756-1212 Fax: 580-229-2333


Company News
Astellas (ALPMY) Snaps Up Stem Cell Pioneer Ocata in $379 Million Deal 11/10/2015 6:07:58 AM
Ocata Therapeutics To Host Conference Call And Webcast To Provide Corporate Update For The Third Quarter 11/9/2015 11:37:47 AM
Ocata Therapeutics To Present At Ladenburg Thalmann 2015 Healthcare Conference 9/23/2015 12:31:40 PM
Canine Patients Treated With Ocata Therapeutics’s Hemangio-Derived Mesenchymal Cells (HMC) Achieve Remission In A Model Of Crohn’s Disease 9/22/2015 10:34:50 AM
First Patient Enrolled In Ocata Therapeutics’ Phase II Study For Dry AMD 9/8/2015 11:28:53 AM
Dr. Robert Lanza, Chief Scientific Officer Of Ocata Therapeutics Awarded The Honor Of iPSC Industry Influencer 9/3/2015 10:49:43 AM
Ocata Therapeutics Receives SBIR Grant From The NIH’s National Eye Institute To Develop Proprietary Photoreceptor Progenitor Cell Therapy For Retinitis Pigmentosa 9/1/2015 11:03:39 AM
Ocata Therapeutics Appoints Dr. Brian Levy To Its Board Of Directors 8/31/2015 8:50:59 AM
Ocata Therapeutics Receives SBIR Grant From NIH To Develop Proprietary Hemangio-Derived Mesenchymal Cell Therapy For Lupus Nephritis 8/24/2015 7:57:45 AM
Ocata Therapeutics Secures $10 Million In Debt Financing 8/19/2015 8:11:21 AM